inclusion criteria: potential participants must satisfy all of the following: laboratory-confirmed* diagnosis of severe acute respiratory syndrome-coronavirus-2 infection within 10 days prior to randomisation age ≥ 18 years a) systolic blood pressure (sbp) ≥ 120 mmhg or b) sbp ≥ 115 mmhg and currently treated with a non-renin angiotensin aldosterone system inhibitor blood pressure (bp) lowering agent that can be ceased participant and treating clinician are willing and able to perform trial procedures. either intended for hospital admission for management of covid-19, or (in australia only) intended for management at home with one or more of the following criteria: age≥60 years body mass index ≥30kg/m2 (derived from the patient's self-report of their height and weight where these are not measured directly) diagnosis of diabetes defined as hba1c ≥7% and/or the consumption of glucose lowering medication history of cardiovascular disease history of chronic respiratory illness currently treated with immunosuppression

inclusion criteria: potential participants must satisfy all of the following: laboratory-confirmed* diagnosis of severe acute respiratory syndrome-coronavirus-2 infection within 10 days prior to randomisation age ≥ 18 years a) systolic blood pressure (sbp) ≥ 120 mmhg or b) sbp ≥ 115 mmhg and currently treated with a non-renin angiotensin aldosterone system inhibitor blood pressure (bp) lowering agent that can be ceased participant and treating clinician are willing and able to perform trial procedures. either intended for hospital admission for management of covid-19, or (in australia only) intended for management at home with one or more of the following criteria: age≥60 years body mass index ≥30kg/m2 (derived from the patient's self-report of their height and weight where these are not measured directly) diagnosis of diabetes defined as hba1c ≥7% and/or the consumption of glucose lowering medication history of cardiovascular disease history of chronic respiratory illness currently treated with immunosuppression

inclusion criteria: potential participants must satisfy all of the following: laboratory-confirmed* diagnosis of sars-cov-2 infection within 10 days prior to randomisation age ≥ 18 years a) systolic blood pressure (sbp) ≥ 120 mmhg or b) sbp ≥ 115 mmhg and currently treated with a non-raasi blood pressure (bp) lowering agent that can be ceased participant and treating clinician are willing and able to perform trial procedures. either intended for hospital admission for management of covid-19, or (in australia only) intended for management at home with one or more of the following criteria: age≥60 years bmi ≥30kg/m2 (derived from the patient's self-report of their height and weight where these are not measured directly) diagnosis of diabetes defined as hba1c ≥7% and/or the consumption of glucose lowering medication history of cardiovascular disease history of chronic respiratory illness currently treated with immunosuppression

inclusion criteria: potential participants must satisfy all of the following: laboratory-confirmed* diagnosis of sars-cov-2 infection within 10 days prior to randomisation age ≥ 18 years a) systolic blood pressure (sbp) ≥ 120 mmhg or b) sbp ≥ 115 mmhg and currently treated with a non-raasi blood pressure (bp) lowering agent that can be ceased participant and treating clinician are willing and able to perform trial procedures. either intended for hospital admission for management of covid-19, or (in australia only) intended for management at home with one or more of the following criteria: age≥60 years bmi ≥30kg/m2 (derived from the patient's self-report of their height and weight where these are not measured directly) diagnosis of diabetes defined as hba1c ≥7% and/or the consumption of glucose lowering medication history of cardiovascular disease history of chronic respiratory illness currently treated with immunosuppression

inclusion criteria: potential participants must satisfy all of the following: 1. laboratory-confirmed* diagnosis of sars-cov-2 infection within 10 days prior to randomisation 2. age ≥ 18 years 3. a) systolic blood pressure (sbp) ≥ 120 mmhg or b) sbp ≥ 115 mmhg and currently treated with a non-raasi blood pressure (bp) lowering agent that can be ceased 4. participant and treating clinician are willing and able to perform trial procedures. 5. either intended for hospital admission for management of covid-19, or (in australia only) intended for management at home with one or more of the following criteria: 1. age≥60 years 2. bmi ≥30kg/m2 (derived from the patient's self-report of their height and weight where these are not measured directly) 3. diagnosis of diabetes defined as hba1c ≥7% and/or the consumption of glucose lowering medication 4. history of cardiovascular disease 5. history of chronic respiratory illness 6. currently treated with immunosuppression

inclusion criteria: potential participants must satisfy all of the following: 1. laboratory-confirmed* diagnosis of sars-cov-2 infection within 10 days prior to randomisation 2. age ≥ 18 years 3. a) systolic blood pressure (sbp) ≥ 120 mmhg or b) sbp ≥ 115 mmhg and currently treated with a non-raasi blood pressure (bp) lowering agent that can be ceased 4. participant and treating clinician are willing and able to perform trial procedures. 5. either intended for hospital admission for management of covid-19, or (in australia only) intended for management at home with one or more of the following criteria: 1. age≥60 years 2. bmi ≥30kg/m2 (derived from the patient's self-report of their height and weight where these are not measured directly) 3. diagnosis of diabetes defined as hba1c ≥7% and/or the consumption of glucose lowering medication 4. history of cardiovascular disease 5. history of chronic respiratory illness 6. currently treated with immunosuppression

inclusion criteria: potential participants must satisfy all of the following: 1. laboratory-confirmed diagnosis of sars-cov-2 infection 2. age ≥ 18 years 3. a) systolic blood pressure (sbp) ≥ 125 mmhg or b) sbp ≥ 115 mmhg and currently treated with a non-raasi blood pressure (bp) lowering agent that can be ceased 4. participant and treating staff are willing and able to perform trial procedures. 5. either intended for hospital admission for management of covid-19, or intended for management at home with one or more of the following criteria: 1. age≥60 years 2. bmi ≥30kg/m2 (derived from the patient's self report of their height and weight where these are not measured directly) 3. diagnosis of diabetes with hba1c ≥7% or on glucose lowering medication 4. history of cardiovascular disease 5. history of chronic respiratory illness 6. currently treated with immunosuppression 6. a) for those intended for hospital admission, the diagnosis (i.e. date of test result) for sars-cov-2 infection must be within 3 days prior to randomisation, or b) for those intended for management at home, the diagnosis (i.e. date of test result) for sars-cov-2 infection must be within 7 days prior to randomisation

inclusion criteria: potential participants must satisfy all of the following: 1. laboratory-confirmed diagnosis of sars-cov-2 infection 2. age ≥ 18 years 3. a) systolic blood pressure (sbp) ≥ 125 mmhg or b) sbp ≥ 115 mmhg and currently treated with a non-raasi blood pressure (bp) lowering agent that can be ceased 4. participant and treating staff are willing and able to perform trial procedures. 5. either intended for hospital admission for management of covid-19, or intended for management at home with one or more of the following criteria: 1. age≥60 years 2. bmi ≥30kg/m2 (derived from the patient's self report of their height and weight where these are not measured directly) 3. diagnosis of diabetes with hba1c ≥7% or on glucose lowering medication 4. history of cardiovascular disease 5. history of chronic respiratory illness 6. currently treated with immunosuppression 6. a) for those intended for hospital admission, the diagnosis (i.e. date of test result) for sars-cov-2 infection must be within 3 days prior to randomisation, or b) for those intended for management at home, the diagnosis (i.e. date of test result) for sars-cov-2 infection must be within 7 days prior to randomisation